IN8bio, Inc. (INAB)

IN8bio Statistics

Total Valuation

IN8bio has a market cap or net worth of $9.76 million. The enterprise value is -$256,814.

Market Cap	9.76M
Enterprise Value	-256,814

Important Dates

The last earnings date was Thursday, August 7, 2025, after market close.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

IN8bio has 4.54 million shares outstanding. The number of shares has increased by 93.52% in one year.

Current Share Class	4.54M
Shares Outstanding	4.54M
Shares Change (YoY)	+93.52%
Shares Change (QoQ)	+48.03%
Owned by Insiders (%)	6.14%
Owned by Institutions (%)	19.44%
Float	4.18M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.58
P/TBV Ratio	0.65
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.03, with a Debt / Equity ratio of 0.20.

Current Ratio	7.03
Quick Ratio	6.77
Debt / Equity	0.20
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -165.56% and return on invested capital (ROIC) is -76.32%.

Return on Equity (ROE)	-165.56%
Return on Assets (ROA)	-69.05%
Return on Invested Capital (ROIC)	-76.32%
Return on Capital Employed (ROCE)	-132.78%
Revenue Per Employee	n/a
Profits Per Employee	-$1.33M
Employee Count	18
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -76.32% in the last 52 weeks. The beta is 0.02, so IN8bio's price volatility has been lower than the market average.

Beta (5Y)	0.02
52-Week Price Change	-76.32%
50-Day Moving Average	2.24
200-Day Moving Average	5.51
Relative Strength Index (RSI)	41.98
Average Volume (20 Days)	50,945

Short Selling Information

The latest short interest is 71,412, so 1.57% of the outstanding shares have been sold short.

Short Interest	71,412
Short Previous Month	110,162
Short % of Shares Out	1.57%
Short % of Float	1.71%
Short Ratio (days to cover)	0.62

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-23.13M
Pretax Income	-31.96M
Net Income	-23.89M
EBITDA	-21.12M
EBIT	-23.13M
Earnings Per Share (EPS)	-$9.54

Balance Sheet

The company has $13.23 million in cash and $3.12 million in debt, giving a net cash position of $10.11 million or $2.23 per share.

Cash & Cash Equivalents	13.23M
Total Debt	3.12M
Net Cash	10.11M
Net Cash Per Share	$2.23
Equity (Book Value)	15.24M
Book Value Per Share	3.74
Working Capital	11.79M

Cash Flow

In the last 12 months, operating cash flow was -$17.19 million and capital expenditures -$33,000, giving a free cash flow of -$17.22 million.

Operating Cash Flow	-17.19M
Capital Expenditures	-33,000
Free Cash Flow	-17.22M
FCF Per Share	-$3.79

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

IN8bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-93.52%
Shareholder Yield	-93.52%
Earnings Yield	-242.51%
FCF Yield	-174.81%

Analyst Forecast

The average price target for IN8bio is $108.00, which is 4,923.26% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$108.00
Price Target Difference	4,923.26%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on June 6, 2025. It was a reverse split with a ratio of 1:30.

Last Split Date	Jun 6, 2025
Split Type	Reverse
Split Ratio	1:30

Scores

Altman Z-Score	n/a
Piotroski F-Score	2